window.pageData = {"stock":{"_id":3000000005454,"stockCode":"005454","stockType":"fund","areaCode":"cn","followedNum":51,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5454,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康C","fundSecondLevel":"hybrid","fundStatus":"normal","inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"indexFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"qhkyyljklhpzhhxzqtzjj","fundCollection":{"_id":4000050780000,"exchange":"jjgs","stockType":"fund_collection","stockCode":"50780000","tickerId":50780000,"name":"前海开源基金管理有限公司"},"managers":[{"_id":7000610178750,"name":"范洁","gender":"f","educationCode":"001002","resume":"范洁女士：香港科技大学、北京协和医学院(清华大学医学部)硕士研究生。先后任职于浙商资产管理有限公司、川财证券有限责任公司，2014年加入前海开源基金管理有限公司，曾任投资经理、研究员、基金经理助理，现任前海开源基金管理有限公司权益投资本部总监助理、基金经理。2017年9月起担任前海开源沪港深优势精选灵活配置混合型证券投资基金基金经理。2018年2月起担任前海开源医疗健康灵活配置混合型证券投资基金基金经理。2019年5月起担任前海开源丰鑫灵活配置混合型证券投资基金基金经理(2019年12月转型为前海开源中药研究精选股票型发起式证券投资基金)。2019年7月起担任前海开源裕瑞混合型证券投资基金。2019年7月2日至2020年10月12日担任前海开源裕和混合型证券投资基金基金经理。2020年5月起担任前海开源沪港深大消费主题精选灵活配置混合型证券投资基金基金经理。2020年7月起担任前海开源沪港深智慧生活优选灵活配置混合型证券投资基金基金经理。曾任前海开源裕瑞混合型证券投资基金基金经理(2019年7月2日-2020年11月25日)。","tickerId":610178750,"stockType":"fund_manager","areaCode":"cn","stockCode":"8801475844","exchange":"fm","cnInfoCode":"8801475844","lastUpdated":"2025-04-23T15:00:50.776Z","followedNum":4,"currency":"CNY","workingDate":"2017-09-04T16:00:00.000Z","fundCompanyId":4000050780000,"fundManagerSecondLevel":"hybrid","pinyin":"fj","appointmentDate":"2018-02-08T16:00:00.000Z"}],"hotMetrics":{"fss":{"stockId":3000000005454,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.2048,"f_ind_h_s_r":0.7951999999999999,"f_h_a":70152,"f_h_s_a":6677,"f_ind_h_s_r_c_1y":-0.20310000000000006,"f_ind_h_s_r_c_hy":-0.20230000000000015,"f_ins_h_s_r_c_1y":0.2031,"f_ins_h_s_r_c_hy":0.2023,"last_data_date":"2025-12-30T16:00:00.000Z"},"fpr":{"stockId":3000000005454,"type":"fpr","f_p_r_fys_ssc":9014,"f_p_r_fys_ssrp":0.21358038388993675,"f_p_r_m1_ssc":9159,"f_p_r_m1_ssrp":0.027407730945621316,"f_p_r_m3_ssc":9014,"f_p_r_m3_ssrp":0.21391323643625873,"f_p_r_m6_ssc":8746,"f_p_r_m6_ssrp":0.9264722698684963,"f_p_r_y1_ssc":8323,"f_p_r_y1_ssrp":0.5414563806777217,"f_p_r_y2_ssc":7709,"f_p_r_y2_ssrp":0.47197716658017647,"f_p_r_y3_ssc":6858,"f_p_r_y3_ssrp":0.8913519031646493,"f_p_r_y5_ssc":4205,"f_p_r_y5_ssrp":0.9964319695528069,"f_cagr_p_r_fs_ssc":9093,"f_cagr_p_r_fs_ssrp":0.6677298724153101},"fp":{"stockId":3000000005454,"type":"fp","f_p_r_fys":0.03089635351176634,"f_p_r_m1":0.06991051454138764,"f_p_r_m3":0.03089635351176634,"f_p_r_m6":-0.14343283582089472,"f_p_r_y1":0.15148475120385285,"f_p_r_y3":-0.13666792027077668,"f_p_r_y5":-0.5932383584945781,"f_cagr_p_r_fs":0.016925762131275945,"f_p_r_d1":-0.009157509157509125,"f_p_r_y2":0.28360545739208387,"last_data_date":"2026-04-02T16:00:00.000Z"},"ff":{"stockId":3000000005454,"type":"ff","f_m_f":7105701,"f_m_f_r":0.012,"f_c_f":1184283,"f_c_f_r":0.002,"f_m_a_c_f":8289984,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2024-12-10T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2025-12-09T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000005454,"type":"f_nlacan","f_nv_d":"2026-04-02T16:00:00.000Z","f_nv":1.1478,"f_nv_cr":-0.013917525773195938},"f_as":{"stockId":3000000005454,"type":"f_as","f_tas":592649992.5186,"f_tas_d":"2025-12-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj"}],"shareholdings":[{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":300347,"holdings":1810000,"marketCap":102627000,"netValueRatio":0.0938,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.022413793103448043,"stock":{"stockCode":"300347","exchange":"sz","stockType":"company","tickerId":300347,"name":"泰格医药"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000009926,"holdings":867000,"marketCap":88489366,"netValueRatio":0.0809,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.1997167138810193,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":603259,"holdings":975900,"marketCap":88455576,"netValueRatio":0.0808,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.19093100062483215,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":688235,"holdings":324993,"marketCap":87293119,"netValueRatio":0.0798,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.12479635060280292,"stock":{"stockCode":"688235","tickerId":688235,"exchange":"sh","stockType":"company","name":"百济神州"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000009606,"holdings":306600,"marketCap":82579706,"netValueRatio":0.0755,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.17986798679867977,"stock":{"exchange":"hk","stockType":"company","stockCode":"09606","tickerId":9606,"name":"映恩生物-B"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000001801,"holdings":929000,"marketCap":63980717,"netValueRatio":0.0585,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.2090248962655593,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":603590,"holdings":1534600,"marketCap":61000350,"netValueRatio":0.0558,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.26115241635687714,"stock":{"stockCode":"603590","exchange":"sh","stockType":"company","tickerId":603590,"name":"康辰药业"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000006990,"holdings":154700,"marketCap":54801374,"netValueRatio":0.0501,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.2369649805447468,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物-B"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000002269,"holdings":1725500,"marketCap":48999432,"netValueRatio":0.0448,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.23279648609077586,"stock":{"stockCode":"02269","exchange":"hk","stockType":"company","tickerId":2269,"name":"药明生物"}},{"date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","fundId":3000000005453,"stockId":1000000000002268,"holdings":888500,"marketCap":48752541,"netValueRatio":0.0446,"quarterlyChange":-0.22413793103448254,"stock":{"stockCode":"02268","exchange":"hk","stockType":"company","tickerId":2268,"name":"药明合联"}}],"profile":{"m":{"date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","managers":[{"name":"范洁","d":"本基金的基金经理、公司投资副总监","wy":12,"md":"范洁女士,香港科技大学、北京协和医学院（清华大学医学部）硕士。先后任职于浙商资产管理股份有限公司、川财证券有限责任公司；2014年7月加盟前海开源基金管理有限公司，曾任研究员、基金经理助理、投资经理，现任公司投资副总监、基金经理。","ad":"2018-02-08T16:00:00.000Z"}]}}},"list":[{"_id":"69ce650df45dd25f43f625a4","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","stockId":3000000005453,"sao":"2025年全年，医药行业股价整体有一定表现，申万医药生物指数全年震荡，9月份之后回撤较明显，全年申万医药生物指数上涨5.25%，创新药指数表现显著好于医药整体，同时，港股创新药指数的表现更为突出。回顾2025年全年医药行业的表现，我们认为产业趋势的变化已经在逐步酝酿，而股价往往先于基本面进行演绎。在2025年度本组合重仓了创新药板块，特别是港股创新药，在2025年三季度本基金逐步开始增加CXO板块的配置，更加聚焦创新药行业龙头及CXO行业龙头。本基金将加强对行业基本面的研究和对宏观趋势的把握，通过自上而下的分析方法对于医药细分子行业进行配置上的调整，通过自下而上的分析方法对个股的基本面、估值水平等进行投资价值判断，同时本基金淡化整体仓位择时，主要通过动态调整内部持仓结构以优化产品表现，努力提升持有人体验。","lastUpdated":"2026-04-02T12:46:05.554Z","mo":"展望2026年，我们认为全年流动性将趋于稳定。基本面方面，医药行业产业升级逐步进入兑现期，创新药部分全球多中心三期临床数据将在2026年陆续读出，CXO板块景气度逐步上行，医疗器械板块在逐步企稳的同时部分创新成果也开始进入收获期。从估值角度来看，我们认为当前时点医药行业具备配置价值。我们判断2026年医药行业的行情相较于2025年会更加多样化，不同的方向都存在投资亮点，主要看好的方向包括创新药、医药研发产业链、部分创新医疗器械和AI在医药当中的应用，本基金持仓将以具有竞争优势的医药细分领域龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1453594","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ff","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000005453,"sao":"2025年3季度，申万医药生物指数上涨15.91%，恒生医疗保健指数表现显著好于申万医药生物指数，细分领域方面，创新药相关指数和个股表现亮眼，港股创新药整体表现更佳，9月份之后创新药板块进入震荡区间。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现。2025年3季度本产品重点配置了具备诞生全球重磅单品潜力的创新药企业和部分创新药产品研发进入收获期的传统医药企业，此外，本基金看好全球流动性改善大背景下医药企业研发和生产外包的需求复苏，在3季度增加了对于CXO板块的配置。医药行业主要由研发驱动，本轮创新药行情本质在于研发投入从量变到质变的供给端改善以及海外专利到期后跨国药企的需求端共振。本基金将加强对行业基本面的研究和对宏观趋势的把握，通过自上而下的分析方法对于医药细分子行业进行配置上的调整，通过自下而上的分析方法对个股的基本面、估值水平等进行投资价值判断，力争获得持续稳定的超额回报。","lastUpdated":"2026-03-09T13:18:40.311Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1375108","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833fe","date":"2025-06-29T16:00:00.000Z","stockId":3000000005453,"sao":"2025年上半年，医药行业呈现典型的结构性行情，申万医药生物指数震荡上行，创新药表现显著好于医药整体，同时，港股创新药的表现更为突出。回顾上半年医药不同领域的表现，我们认为自上而下的产业趋势有希望带动医药行业走出一轮可持续的行情。在2025年度上半年组合重仓了创新药板块。本基金将加强对行业基本面的研究和对宏观趋势的把握，通过自上而下的分析方法对于医药细分子行业进行配置上的调整，通过自下而上的分析方法对个股的基本面、估值水平等进行投资价值判断，同时本基金淡化整体仓位择时，主要通过动态调整内部持仓结构以期优化产品表现，努力提升持有人体验。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.308Z","mo":"展望2025年下半年，流动性方面，我们认为流动性整体处于边际改善过程中。基本面方面，医药行业产业升级逐步进入兑现期，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。从估值角度和行业基本面来看，我们认为当前时点医药行业具备配置价值。我们判断2025年医药行业将以结构性的个股和部分细分领域的机会为主，主要看好的方向包括创新药的商业化进程、具备竞争优势的品种出海和医药研发产业链的需求端恢复，本基金持仓将以具有竞争优势的医药细分领域龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1341310","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833fd","date":"2025-03-30T16:00:00.000Z","stockId":3000000005453,"sao":"2025年1季度，医药行业亮点较多，申万医药生物指数微涨，恒生医疗保健指数表现显著好于申万医药生物指数，细分领域方面，创新药相关指数和个股表现亮眼。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现。2025年初的AI应用端关注度提升带来全市场对于中国创新类资产关注度的提升和资产价值的再评估，2025年1季度本产品重点配置了具有更高成长弹性的创新药、具有国际竞争力的创新医疗器械，同时，基于对行业需求周期的判断，本基金增加了在CXO板块的配置。本基金将加强对行业基本面的研究和对宏观趋势的把握，通过自上而下的分析方法对于医药细分子行业进行配置上的调整，通过自下而上的分析方法对个股的基本面、估值水平等进行投资价值判断，力争获得持续稳定的超额回报。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.305Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1270315","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833fc","date":"2024-12-30T16:00:00.000Z","stockId":3000000005453,"sao":"2024年全年，医药行业呈现震荡向下走势，申万医药生物指数全年表现较弱，投资机会更多是以结构性的个股机会为主，在这个过程中，高成长个股和稳健成长的高股息个股整体表现优于医药大盘。回顾全年医药个股的表现，我们认为个股的表现拉长时间周期来看仍然是和其基本面高度相关的。在2024年度基金经理保持组合中各细分领域相对均衡的配置，其中具有稳健需求的中药和成长弹性的创新药维持了相对高的配置比例，在4季度本产品增加了具有国际竞争力的创新医疗器械以及行业周期底部区间的CXO板块的配置。本基金将加强对行业基本面的研究和对宏观趋势的把握，通过自上而下的分析方法对于医药细分子行业进行配置上的调整，通过自下而上的分析方法对个股的基本面、估值水平等进行投资价值判断，同时本基金淡化整体仓位择时，主要通过动态调整内部持仓结构以优化产品表现。努力提升持有人体验。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.302Z","mo":"展望2025年，流动性方面，我们认为流动性整体处于边际改善过程中。基本面方面，医药行业回归经营常态，各项政策的逐步落地将促进行业长期的产业结构升级，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。从估值角度和行业基本面来看，我们认为当前时点医药行业具备配置价值。我们判断2025年医药行业将以结构性的个股和部分细分领域的机会为主，主要看好的方向包括创新药的商业化进程和具备竞争优势的品种出海、中药行业内的龙头份额提升及行业整合、医疗器械的产品放量周期以及医药研发产业链的需求端恢复，本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1252044","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833fb","date":"2024-09-29T16:00:00.000Z","stockId":3000000005453,"sao":"2024年3季度，医药行业经历了一段震荡运行后迅速上涨，上涨幅度在全市场各行业中相对靠前，其中，前期跌幅较大的医疗服务、CRO行业涨幅居前，此前由于一些市场担忧导致下跌的中药OTC品种也迅速反弹。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，2024年3季度本产品主要配置了具有成长弹性的创新药、创新医疗器械以及具有稳健需求的中药等。此外，美联储开启降息周期，本基金看好当前时点港股医药整体的估值体系重估，此前在历史低位布局了部分优质的港股创新药标的。本基金将加强对行业基本面的研究和对宏观趋势的把握，自上而下对于行业大方向进行配置上的把握以及个股的投资价值判断，力争获得持续稳定的超额回报。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.300Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1177422","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833fa","date":"2024-06-29T16:00:00.000Z","stockId":3000000005453,"sao":"2024年上半年，医药行业呈现震荡向下走势，投资机会更多是以结构性的个股机会为主，在这个过程中，高成长个股和稳健成长的高股息个股整体表现优于医药大盘。基金经理保持了组合对于中药和创新药相对高的配置比例，此外，本基金看好港股医药的投资机会，在历史低位布局了部分港股医药标的。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过动态调整内部持仓结构以优化产品表现。努力提升持有人体验。","declarationDate":"2024-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.297Z","mo":"展望2024年下半年，流动性方面，尽管无法准确判断美联储的降息时间点及降息节奏，但我们根据其宏观数据表现可以判断降息时间点是逐步临近的。基本面方面，医药行业回归经营常态，各项政策的逐步落地将促进行业长期的产业结构升级，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。从估值角度和行业基本面来看，我们认为当前时点医药行业具备配置价值，截至2024年6月30日，申万医药生物指数静态估值处于过去10年的中位数之下，我们判断2024年医药行业将以结构性的个股和部分细分领域的机会为主，主要看好的方向包括医药行业出海、创新药的商业化进程、中药的产业升级等，本基金金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1146376","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f9","date":"2024-03-30T16:00:00.000Z","stockId":3000000005453,"sao":"2024年1季度，医药行业震荡下行，在全市场各行业中表现偏弱，投资机会更多是结构性的个股机会为主。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现。2024年1季度本产品主要配置了稳健增长的中药板块以及部分具有成长弹性的药品、器械等板块，此外，本基金看好当前时点港股医药的投资机会，在历史低位布局了部分港股医药标的。本基金将加强对行业基本面的研究和对宏观趋势的把握，进一步把握产业周期运行规律，力争获得持续稳定的超额回报。","declarationDate":"2024-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.294Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1072961","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f8","date":"2023-12-30T16:00:00.000Z","stockId":3000000005453,"sao":"2023年全年，医药行业呈现震荡向下走势，投资机会更多是以结构性的个股机会为主，在这个过程中，中药行业整体表现优于医药大盘。基金经理基于对中药行业长期发展趋势的看好在组合中增加了中药行业的配置，同时增加了创新药的配置比例，此外，因看好港股医药的投资机会，在历史低位布局了部分港股医药标的。本基金看好医药行业的长期发展机会，基于个股和行业基本面、边际变化和投资性价比对不同细分领域的龙头企业进行配置，同时本基金淡化整体仓位择时，主要通过动态调整内部持仓结构以优化产品表现。努力提升持有人体验。","declarationDate":"2024-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.291Z","mo":"展望2024年，流动性方面，美联储加息周期结束，尽管无法准确判断美联储的加息周期结束时间点，但我们可以判断降息伴随着时间推移是越来越近的。基本面方面，医药行业在经历疫情的扰动之后回归到常态，各项政策的逐步落地将促进行业长期的产业结构升级，但同时也需要关注由于外部因素导致的子行业内部需求和供给的变化，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。从估值角度和行业基本面来看，我们2024全年看好医药行业的表现，我们判断2024年医药行业将以结构性的个股和部分细分领域的机会为主，主要看好的方向包括医药行业出海、消费医疗的复苏、科研产业链的需求回暖、创新药的整合并购、中药的产业升级，本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1058368","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f7","date":"2023-09-29T16:00:00.000Z","stockId":3000000005453,"sao":"2023年三季度，医药行业震荡下行，申万医药生物指数下跌1.57%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现。2023年三季度本产品重点布局了中药和创新药板块，同时基于对长期趋势的看好布局了药店板块，本基金将加强对行业基本面的研究和对宏观趋势的把握，进一步把握产业周期运行规律，力争获得持续稳定的超额回报。","declarationDate":"2023-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.289Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2023年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=990110","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f6","date":"2023-06-29T16:00:00.000Z","stockId":3000000005453,"sao":"2023年上半年，医药行业整体表现相对动荡，年初延续了2022年四季度的上涨态势，之后进入下行通道，在这个过程中，中药行业整体表现优于医药大盘，2023年上半年申万医药生物指数下跌5.56%。在这个过程中基金经理基于对中药行业长期发展趋势的看好在组合中增加了中药行业的配置，除此之外的个股和行业配置相对分散。基金经理在对本组合进行管理时重点关注公司长期成长空间、短期基本面边际改善以及基本面和估值的匹配程度。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构和个股仓位以优化产品表现，努力提升持有人体验。","declarationDate":"2023-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.286Z","mo":"展望2023年下半年，流动性方面，美联储加息周期进入下半场，尽管无法准确判断美联储的加息周期结束时间点，但我们可以从每次加息力度上判断出利率上行的速度正在放缓，加息周期对于市场的边际影响在减弱。基本面方面，医药行业在经历疫情的扰动之后回归到常态，各项政策的逐步落地将促进行业长期的产业结构升级，但同时也需要关注由于外部因素导致的子行业内部需求和供给的变化，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。我们全年看好以创新药为代表的创新产业链表现以及以中药、院内诊疗恢复为代表的复苏主线，本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=965500","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f5","date":"2023-03-30T16:00:00.000Z","stockId":3000000005453,"sao":"2023年一季度，医药行业先涨后跌，整体呈现震荡走势，申万医药生物指数上涨1.86%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，2023年一季度本产品基于对中药行业发展前景的看好增加了在中药板块的配置，本基金将加强对行业基本面的研究和对宏观趋势的把握，进一步把握产业周期运行规律，力争获得持续稳定的超额回报。","declarationDate":"2023-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.284Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2023年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=886978","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f4","date":"2022-12-30T16:00:00.000Z","stockId":3000000005453,"sao":"2022年全年市场表现相对动荡，医药行业全年表现相对较弱，2022年申万医药生物指数下跌20.34%。2022年本产品基金经理在管理组合过程中忽视了几个方面的问题：一是全球宏观流动性对于二级市场和一级市场流动性的影响，二是交易结构的拥挤度对于个股中短期股价表现的影响，三是子行业产业生命周期发展阶段不同对于定价锚的影响。后续基金经理在加强个股基本面跟踪研究的基础上，会加强对上述因素的研究和跟踪，同时通过均衡配置的方法减少因单一子行业波动带来的对基金表现的影响，在市场情绪较为极端时增大估值在投资考量因素中的权重，本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构和对个股仓位的调整以优化产品表现，努力提升持有人体验。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.281Z","mo":"展望2023年，流动性方面，美联储加息周期进入下半场，尽管无法准确判断美联储的加息周期结束时间点，但我们可以从每次加息力度上判断出利率上行的速度正在放缓，加息周期对于市场的边际影响在减弱。基本面方面，医药行业在经历疫情的扰动之后回归到常态，各项政策的逐步落地将促进行业长期的产业结构升级，但同时也需要关注由于外部因素导致的子行业内部需求和供给的变化，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。我们全年看好以创新药、服务外包提供商和上游科研服务提供商为代表的创新产业链表现，以及受益于政策支持和刚需属性的复苏主线，本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=869855","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f3","date":"2022-09-29T16:00:00.000Z","stockId":3000000005453,"sao":"2022年三季度，医药行业经历了4月底的反弹后持续下跌，申万医药生物指数下跌15.98%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，本基金主要通过子行业分散的方法来减少因单一子行业波动带来的影响，同时在市场情绪较为极端时增大估值在投资考量因素中的权重，在总结过去经验的基础上，本基金同时将加强对和医药行业联系较紧密的外部宏观因素的跟踪和前瞻判断，进一步把握产业周期运行规律，力争获得持续稳定的超额回报。","declarationDate":"2022-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.278Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2022年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=805288","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f2","date":"2022-06-29T16:00:00.000Z","stockId":3000000005453,"sao":"2022年上半年市场表现相对动荡，医药行业年初开始跟随大盘出现大幅下跌，之后迎来反弹，但相对于大盘医药整体反弹力度偏弱，反弹节奏也相对滞后， 2022年上半年申万医药生物指数下跌14.24%。后续我们将在加强对个股基本面跟踪研究的基础上，通过对宏观因素的研究从更高的维度把握医药行业中子行业变化的周期性，同时通过均衡配置的方法减少因单一子行业波动带来的对基金表现的影响，在市场情绪较为极端时增大估值在投资考量因素中的权重。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构和对个股仓位的调整以优化产品表现，努力提升持有人体验。","declarationDate":"2022-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.276Z","mo":"展望2022年下半年，流动性方面，美联储加息周期进入下半场，对于市场的边际影响在减弱，基本面方面，医药行业在经历疫情的扰动之后回归到常态，各项政策的逐步落地将促进行业长期的产业结构升级，但同时也需要关注由于外部因素导致的子行业内部需求和供给的变化，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=784158","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f1","date":"2022-03-30T16:00:00.000Z","stockId":3000000005453,"sao":"2022年一季度，医药行业整体呈现震荡走势，2022年一季度申万医药生物指数下跌10.79%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，努力提升持有人体验，本基金主要通过子行业分散的方法来减少因单一子行业波动带来的影响，力争获得持续稳定的超额回报。","declarationDate":"2022-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.273Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2022年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=725012","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833f0","date":"2021-12-30T16:00:00.000Z","stockId":3000000005453,"sao":"2021年市场表现相对动荡，医药行业在春节前经历了快速上涨后又在春节后出现大幅下跌，之后迎来快速反弹，下半年受多方面因素影响，医药生物行业整体持续下行，2021年全年申万医药生物指数下跌5.73%。行业内的权重股整体表现弱于医药指数。2021年基金经理在构建组合时，出发点是基于对医药行业创新产业链长期前景的看好以及相关子行业基本面表现的确定性，但由于对基本面的关注和中长期前景的关注过多，忽视了短期外部宏观因素的扰动、行业的周期性以及市场情绪在个股股价表现中的影响，因此使得产品整体的表现不理想，2022年基金经理在加强对个股基本面跟踪研究的基础上，将通过对宏观因素的研究从更高的维度把握医药行业中子行业变化的周期性，同时通过均衡配置的方法减少因单一子行业波动带来的对基金表现的影响，本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构和对个股仓位的调整以优化产品表现，努力提升持有人体验。","declarationDate":"2022-01-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.270Z","mo":"展望2022年，医药行业回归到高质量长期发展的轨道，各项政策的逐步落地将促进行业长期的产业结构升级，但同时也需要关注由于外部因素导致的子行业内部需求和供给的变化，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=712823","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ef","date":"2021-09-29T16:00:00.000Z","stockId":3000000005453,"sao":"2021年三季度，医药行业在经历了前期快速反弹后再次下跌，2021年三季度申万医药生物指数下跌13.68%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，努力提升持有人体验，力争获得持续稳定的超额回报。","declarationDate":"2021-10-26T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.268Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2021年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=655904","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ee","date":"2021-06-29T16:00:00.000Z","stockId":3000000005453,"sao":"2021年上半年，市场表现相对动荡，医药行业在春节前经历了快速上涨后又在春节后出现大幅下跌，之后迎来快速反弹，部分权重股经历大幅回调后又创新高，2021年上半年申万医药生物指数上涨9.33%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化整体仓位择时，主要通过调整内部持仓结构以优化产品表现，努力提升持有人体验。","declarationDate":"2021-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.265Z","mo":"展望2021年下半年，疫情对行业的边际影响逐步减弱，医药行业回归到高质量长期发展的轨道，各项政策的逐步落地将促进行业长期的产业结构升级，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=633030","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ed","stockId":3000000005453,"sao":"2021年一季度，医药行业呈现出前涨后跌的态势，部分权重股由于短期涨幅过大出现较大幅度的回调，2021年一季度申万医药生物指数下跌4.06%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化仓位择时，主要通过调整内部持仓结构以降低产品回撤，努力提升持有人体验，力争获得持续稳定的超额回报。","date":"2021-03-30T16:00:00.000Z","declarationDate":"2021-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.262Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2021年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=572130","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ec","stockId":3000000005453,"sao":"由于疫情使得行业关注度提升，2020年上半年医药行业大幅上涨，但8月份之后行业震荡下行，申万医药生物指数上涨51.10%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时本基金淡化仓位择时。投资策略方面，本基金的个股选择以自下而上选股为主，选择优质公司长期伴随成长，在不同的市场风格下，主要通过调整内部持仓结构以降低产品回撤，努力提升持有人体验。","date":"2020-12-30T16:00:00.000Z","declarationDate":"2021-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.260Z","mo":"展望2021年，疫情对行业的边际影响逐步减弱，医药行业回归到高质量长期发展的轨道，各项政策的逐步落地将促进行业长期的产业结构升级，从终端需求和行业升级迭代的角度来看，医药行业仍然是值得长期投资的优质赛道。本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报。","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2020年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=559237","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833eb","stockId":3000000005453,"sao":"由于行业短期涨幅过大，2020年三季度医药行业整体呈现震荡行情，申万医药生物指数上涨2.93%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股，同时通过及时调整持仓结构以降低产品回撤，努力提升持有人体验，力争获得持续稳定的超额回报。","date":"2020-09-29T16:00:00.000Z","declarationDate":"2020-10-27T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.257Z","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2020年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=489647","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aec8b07fea5b3eb04833ea","stockId":3000000005453,"sao":"由于疫情带来的行业关注度提升，2020年上半年医药行业大幅上涨，申万医药生物指数上涨40.28%。本基金看好医药行业的长期发展机会，重点配置了医药不同细分领域的龙头股。","date":"2020-06-29T16:00:00.000Z","declarationDate":"2020-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:18:40.254Z","mo":"展望2020年下半年，疫情对行业的边际影响逐步减弱，医药行业回归到高质量长期发展的轨道，医药行业仍然是值得长期投资的优质赛道。本基金持仓将以具有竞争优势的医药细分子行业龙头企业为主，力争获得持续稳定的超额回报","fund":{"_id":3000000005453,"stockCode":"005453","stockType":"fund","areaCode":"cn","followedNum":100,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":null,"ipoDate":"2017-12-10T16:00:00.000Z","setUpScale":359896000,"market":"a","tickerId":5453,"custody":"中国银行股份有限公司","name":"前海开源医疗健康灵活配置混合型证券投资基金","shortName":"前海开源医疗健康A","fundSecondLevel":"hybrid","__csrcFundId":5004,"fundStatus":"normal","lastUpdated":"2024-12-31T23:39:43.100Z","masterFundFlag":1,"inceptionDate":"2018-01-18T16:00:00.000Z","fundCollectionId":4000050780000,"currency":"CNY","memoNum":1,"masterFundShortName":"前海开源医疗健康","pinyin":"qhkyyljklhpzhhxzqtzjj","managers":[{"stockCode":"8801475844","stockType":"fund_manager","exchange":"fm","tickerId":610178750,"name":"范洁"}]},"announcement":{"linkText":"前海开源医疗健康灵活配置混合型证券投资基金2020年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=464899","linkType":"PDF","source":"csrc_pdf"}}]}